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Abstract
Background: Smoking is reported to affect the risk of a number of chronic disorders, including rheumatic diseases.
Previous cross-sectional studies have shown a lower frequency of smoking in patients with primary Sjögren’s
syndrome (pSS). The aim of this study was to investigate the impact of smoking and socioeconomic status on the
risk of subsequent diagnosis of pSS in a nested case-control study.
Method: Participants in two large population-based health surveys who were later diagnosed with pSS were identified
through linkage with the Malmö Sjögren’s Syndrome Register. Matched controls were obtained from the health surveys.
Results: Sixty-three patients with pSS with pre-diagnostic data from the health surveys were identified. Current smoking
was associated with a significantly lower risk of later being diagnosed with pSS (odds ratio (OR) 0.3; 95% CI 0.1–0.6).
Furthermore, former smoking was associated with an increased risk of subsequent pSS diagnosis (OR 4.0; 95% CI 1.8–8.8)
compared to never smoking. Similar results were found in a sub-analysis of patients with reported symptom onset after
inclusion in the health surveys. Socioeconomic status and levels of formal education had no significant impact on the risk
of later being diagnosed with pSS.
Conclusion: In this nested case-control study, current smoking was associated with a reduced risk of subsequent
diagnosis of pSS. In addition, former smoking was associated with an increased risk. Whether this reflects a biological
effect of cigarette smoking or other mechanisms should be further investigated in future studies.
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Background
Primary Sjögren’s syndrome (pSS) is an autoimmune
disease primarily affecting the salivary and lacrimal
glands, causing oral and ocular dryness. Other organs
such as lungs, kidneys, nervous system, and skin may
also be affected in the disease [1]. pSS is associated with
B-cell activation, presence of various autoantibodies, sys-
temic symptoms and an increased risk of non-Hodgkin
lymphoma [2, 3]. The onset of the disease is often insidi-
ous and development of autoantibodies is seen years
before onset of clinical disease [4, 5].
The estimated prevalence varies widely. When using
the American European consensus group criteria (AECG
criteria) [6] the prevalence of pSS is estimated to be
between 11.3 and 236.1/100,000 in different European
populations. Annual incidence estimates vary between
3.1 and 5.3/100000 [7].
The aetiopathogenesis of pSS is poorly understood but
it entails genetic factors [8], hormonal factors [9] and pos-
sible viral infections [10], while environmental triggers are
less well-studied. Smoking is a widely known risk factor
for several malignant diseases [11, 12], but also for chronic
inflammatory disorders such as rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE) and Crohn’s disease
[13, 14]. Retrospective studies and studies with exposure
measured before diagnosis [15–17] in RA indicate that
smoking is particularly associated with seropositive RA. In
some diseases, such as ulcerative colitis, Behcet’s disease
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and Parkinson’s disease, smoking seems to have a protect-
ive effect [18–20]. Only three studies have specifically
addressed the association between smoking and pSS and
in none of them has smoking been assessed prior to pSS
diagnosis [21–23].
The closeness of cigarette smoke to mucosal mem-
branes and exocrine glands, and the effect of the cigarette
smoke on the immune system, makes the influence of
cigarette smoking on the development of pSS interesting.
However, when studying associations with smoking, social
status has to be taken into consideration because it can
correlate with both smoking and other exposures such as
environmental toxins and dietary factors. Finding epi-
demiological risk factors for pSS might help us understand
the underlying pathogenesis and thus guide further
studies. As smoking affects the development of several
diseases, including rheumatic disease, we hypothesized
that smoking also might affect the development of pSS.
To our knowledge, this is the first nested case-control
study on the relationship between smoking and socioeco-
nomic status and subsequent diagnosis of pSS.
Method
Aim
The aim of this study was to investigate the impact of
smoking and socioeconomic status on the risk of later
being diagnosed with pSS.
Source populations
This nested case-control study used information from
the Malmö Preventive Medicine Project (MPMP) and
the Malmö Diet and Cancer Study (MDCS). The MPMP
is a health survey performed in Malmö, Sweden (current
population approximately 320,000, at the time of the
survey 235,000) between 1974 and 1991 entailing 33,346
individuals. Of these, 22,444 were men born between
1921 and 1938 and 10,902 were women born between
1925 and 1938. The main purpose of the MPMP was to
study risk factors for cardiovascular disease and alcohol
abuse. Details on the recruitment have been described
previously [24]. The overall participation rate was 71%.
The MDCS is a health survey performed in Malmö
between 1991 and 1996 that included 30,447 individuals
born between 1923 and 1945. The total source popula-
tion was 74,138, and the participation rate was 41%. The
survey has been described in detail previously [24, 25].
The main purpose of the MDCS was to study risk fac-
tors for cancer.
Exposure information
Participants in the health surveys filled out self-
administered questionnaires on personal and medical in-
formation, including smoking and level of education. After
merging data from the MPMP and the MDCS, cases and
controls were classified as current/not current smokers at
the time of participation in the health survey, and also as
current/former/never smokers. In the MDCS, formal edu-
cation was classified as follows: ≤8 years of elementary
school, 9–10 years, 11–12 years, >12 years and university
degree. In the MPMP, information was available on
whether the individual had attended elementary school,
secondary school or higher education. A low level of for-
mal education was classified in the MDCS as ≤8 years and
in the MPMP as elementary school only.
Information on socioeconomic status had previously been
incorporated in MPMP and MDCS by linking the databases
with data on standardized socioeconomic status by occupa-
tion, based on information from Statistics Sweden, as
previously described in detail [26]. The categorization of
socioeconomic status by Statistics Sweden includes a div-
ision in groups corresponding to working class, middle
class, and a group of self-employed inhabitants. For the
present study, participants were classified as blue-collar
workers or white-collar workers. Blue-collar workers in-
cluded both skilled and unskilled manual workers, corre-
sponding to the working-class group from Statistics
Sweden. White-collar workers included non-manual em-
ployees of high level (occupations normally requiring six
years of post-comprehensive school education, e.g. higher
civil servants and executives), medium level (occupations
normally requiring three years but not six years of post-
comprehensive school education, with or without subordi-
nates) and low level (normally requiring two but not three
years of post-comprehensive school education with or
without subordinates) and self-employed professionals such
as architects and lawyers.
Cases and controls
To identify pSS cases with pre-diagnostic information in
the health surveys, the MPMP and the MDCS were
linked to the Malmö Sjögren’s Syndrome Register
(MSSR). The MSSR is a research database, in which con-
secutive patients with pSS have been included since
1984. At the time of the present study 409 patients were
included in the cohort. Since 2002 only patients fulfilling
the AECG criteria have been included. Patients included
before 2002 have been assessed retrospectively and
classified according to the AECG criteria. Only patients
with a first pSS diagnosis after inclusion in the MPMP
or MDCS, and who fulfilled the AECG criteria, were
included in the present study.
The earliest available data were used for patients included
in both surveys before diagnosis of pSS. Retrospective data
on symptom onset obtained at the time of diagnosis were
collected from the MSSR, thus were independently col-
lected from the exposure data. Four controls for each case,
matched for sex, age and time of inclusion, were obtained
from the corresponding health survey. Controls were
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randomly selected from those who fulfilled the matching
criteria using specially designed software. This nested
case-control study design, based on the same source pop-
ulations, has previously been used in several studies of
predictors of RA [27–30] and giant cell arteritis [31].
Statistics
Potential predictors of pSS were analyzed using conditional
logistic regression (SPSS version 22). Each case and the
corresponding controls were given a group number that
was entered into the logistic regression models as a categor-
ical variable. Analyses were also stratified by time to pSS
diagnosis in the cases (above vs below the median). Separ-
ate analyses included only cases with documented onset of
symptoms after inclusion in the health survey, and the cor-
responding controls.The two-sided Fisher exact test was
used to analyze differences in immunologic markers after
diagnosis of pSS by smoking status at inclusion in the
health survey. A p value <0.05 was considered significant.
Results
Incident cases and controls
A total of 63 incident cases, patients who prior to a first
diagnosis of pSS and fulfilment of the AECG criteria had
been included either in the MPMP, the MDCS, or both,
were identified. These are, from here, designated “pre-pSS
patients”: 252 controls were obtained from the correspond-
ing health surveys. Characteristics of the patients at diagno-
sis are shown in Table 1. The median time between
inclusion in one of the health surveys and subsequent diag-
nosis was 8.2 years (IQR 2.4–14.1). Median age at inclusion
in the health surveys was 51 years, and median age at
diagnosis was 61 years. Demographics and information on
exposures for cases and controls are listed in Table 2.
Smoking and the risk of pSS
Information on smoking status was available in 60 cases.
The distribution of current, former and never smokers dif-
fered between controls and pre-pSS patients with a higher
proportion of former smokers among pre-pSS patients
(Table 2). In conditional logistic regression analysis, current
smoking at the time of inclusion in the health surveys was
associated with a significantly lower risk of later being diag-
nosed with pSS compared to current non-smoking (OR 0.3;
95% CI 0.1–0.6). Former smoking was associated with a
higher risk of being diagnosed with pSS, both compared to
never smoking (OR 4.0; 95% CI 1.8–8.8) and current smok-
ing (OR 7.8; 95% CI 3.1–19.9) (Table 3).
Sensitivity analyses
Retrospective data from the MSSR on symptom onset
were available in 49 cases. There were 28 patients who
had symptom onset >1 year after inclusion in the popula-
tion surveys (range 2–24, median 6.5, IQR 3.25–14.75),
and information on smoking status was available in 26 of
these patients. In analyses restricted to these cases and
their controls, current smoking was still associated with a
lower risk of later being diagnosed with pSS compared
with current non-smoking, and there was a trend towards
an association between former smoking and subsequent
pSS diagnosis (Table 3). In order to answer the question
as to whether cessation of smoking was due to symptoms
of pSS, we analyzed the time window between symptom
onset and cessation of smoking. Among the cases with
symptom onset >1 year after inclusion in the populations
Table 1 Characteristics of incident cases of primary Sjögren’s
syndrome
Characteristic Patients (n = 63)
Sex (male/female) (n) 5/58
Age at diagnosis of pSS (years) 61 (54–69)
Time between inclusion and
diagnosis (years)
8.2 (2.4–14.1)







Lower lip salivary gland biopsy focus score ≥1 85%
Results are presented as numbers, median (IQR) or percentage in cases with
available data. Missing data on time of symptom onset in 15 patients,
Sjögren’s syndrome related antigen A, Ro (anti-SSA), Sjögren’s syndrome
related antigen B, La (anti-SSB) and antinuclear antibodies (ANA) in 1 patient,
rheumatoid factor (RF) in 2 patients and lower lip salivary gland biopsy focus
score in 6 patients. pSS Primary Sjögren’s syndrome
Table 2 Demographic and exposure information in pre-primary






Female sex, n (%) 58/63 (92) 232/252 (92) 1.00
Age at inclusion in the
population survey,
mean (IQR), years
52.6 (49.0–56.0) 52.7 (49.0–56.0) 0.94
Current smoker, n (%a) 10/60 (17) 92/251 (37) 0.003
Former smoker, n (%a) 32/60 (53) 63/251 (25) < 0.001
Never smoker, n (%a) 18/60 (30) 96/251 (38) 0.23
White-collar worker, n (%a) 26/54 (48) 131/236 (56) 0.33
Blue-collar worker, n (%a) 22/54 (41) 89/236 (38) 0.68
Other socioeconomic
status, n (%a)
6/54 (11) 16/236 (7) 0.28
Low level of formal
education, n (%a)
25/58 (43) 99/243 (41) 0.73
Medium/high level of
formal education, n (%a)
33/58 (57) 144/243 (59) 0.73
aPercentage of individuals with available data. **Mann-Whitney U test
Olsson et al. Arthritis Research & Therapy  (2017) 19:50 Page 3 of 8
surveys, there were 12 patients who were former smokers.
The time period between cessation of smoking and symp-
tom onset was >5 years in all these cases.
In the whole group of pre-pSS patients who were former
smokers and for whom information was available on
symptom onset (n = 23), including those with symptom
onset before inclusion in the health surveys, cessation of
smoking occurred >5 years before symptom onset in 20
cases, 4 years before symptom onset in 1 case and after
symptom onset in 1 case.
Socioeconomic status, level of formal education and the
risk of pSS
Socioeconomic status, comparing blue-collar workers
and white-collar workers, did not affect the risk of being
diagnosed with pSS. Furthermore, there was no associ-
ation between the level of formal education and subse-
quent diagnosis of pSS (Table 3).
Stratified analyses
To further examine the relationship between smoking or
other exposures and pSS, analyses were performed separ-
ately in cases with a time period between inclusion in one
of the health surveys and diagnosis of pSS that was above
or below the median (8.2 years) and in the corresponding
controls. The results in these subgroups were similar to
those in the whole group (Table 4).
Anti-Sjögren’s syndrome related antigen A, Ro (anti-SSA)
antibody positivity or presence or absence of focal sialadeni-
tis at the time of diagnosis was not significantly different
between individuals who were currently or not currently
smoking at the time of inclusion in the health surveys, nor
between those who had ever smoked or never smoked, or
those who were currently smoking, were former smokers,
or had never smoked (Table 5).
Discussion
In this study, being a current smoker was associated
with a lower risk of later being diagnosed with pSS.
Former smokers had a higher risk of subsequently being
diagnosed with pSS, compared both to never smokers
and current smokers. The same pattern is seen in ulcera-
tive colitis [18]. In Parkinson’s disease, there is also an
inverse association between cigarette smoking and devel-
opment of the disease [20]. Interestingly, in three previ-
ous studies specifically addressing the association
between smoking and pSS, there were fewer current
smokers and more former smokers among pSS patients.
The first study involved 355 pSS patients in whom there
was a lower frequency of focal sialadenitis in lower lip
biopsies and a lower frequency of anti-SSA positivity in
patients with pSS who were smokers [21]. However, as
the Copenhagen criteria were used, in which the pres-
ence of anti-SSA/SSB or presence of focal sialadenitis
are not mandatory, several patients not fulfilling the
AECG criteria were included in that study. One inter-
pretation of that study is that within a population of in-
dividuals with sicca symptoms, smoking is negatively
associated with markers of autoimmune sialadenitis.
The second study was a cross-sectional study of 140
patients, fulfilling the AECG criteria, in which there
were also more former smokers and fewer current
smokers among patients with pSS [22]. Finally, in a
cross-sectional study of 207 pSS patients fulfilling the
AECG criteria, there were fewer current smokers, but
more former smokers compared to healthy controls [23].
The characteristics of the patients in that study were
similar to the characteristics after diagnosis of the pSS
Table 3 Association between smoking status, socioeconomic status and level of formal education and development of primary
Sjögren’s syndrome
All pSS cases (n = 63)
and matched controls
(n = 252) OR (95% CI)
Exposed
(cases/controls)
pSS cases with documented symptom
onset after inclusion (n = 28)
and matched controls (n = 112) OR (95% CI)
Exposed
(cases/controls)
Smoking Not current smokers Reference 50/159 Reference 22/74
Current smokers 0.3 (0.1–0.6) 10/92 0.2 (0.1–0.9) 4/38
Never smokers Reference 18/96 Reference 10/43
Former smokers 4.0 (1.8–8.8) 32/63 1.7 (0.6–5.6) 12/31
Current smokers 0.5 (0.2–1.3) 10/92 0.3 (0.1–1.5) 4/38
Socioeconomic status White-collar worker Reference 26/131 Reference 11/53
Blue-collar worker 1.4 (0.7–2.8) 22/89 0.8 (0.2–2.5) 9/40
Other 2.4 (0.7–8.4) 6/16 1.0 (0.3–3.2) 4/11
Education Medium/high Reference 33/144 Reference 11/55
Low 1.1 (0.6–2.1) 25/99 1.4 (0.5–4.0) 13/49
Smoking status and level of formal education were assessed at inclusion in the health surveys. Patients were subsequently diagnosed with primary Sjögren’s
syndrome (pSS) after a median of 8.2 years (IQR 2.4–14.1) after inclusion
Olsson et al. Arthritis Research & Therapy  (2017) 19:50 Page 4 of 8
patients in the present study, except that they had a higher
frequency of positive lip biopsies (99.5% compared to 85%
in the present study). In three other studies, which investi-
gated cardiovascular risk factors in patients with pSS,
there were fewer current smokers in one study [32], and
in the other two studies there were fewer ever smokers
[33, 34], compared to controls. In the latter two, there was
no information on the numbers of current and former
smokers.
Smoking is shown to cause a short-term increase in
salivary flow rate (SRF) but a long-term reduced SFR
[35, 36]. Cigarette smoking is also shown to cause ocular
dryness when comparing chronic smokers with healthy
controls [37]. A potential explanation for the smaller
numbers of current smokers and for the greater num-
bers of former smokers in cross-sectional studies of pSS
is that oral and ocular dryness and pulmonary symptoms
make the patients more prone to quit smoking, both
due to dryness and the irritation caused by the smoke.
Interestingly, in this study, cessation of smoking in the
majority of pSS patients who were former smokers did
not occur in close temporal proximity to symptom onset
and the impact of smoking was similar in cases with a
longer and shorter time to diagnosis, supporting the
possibility that smoke cessation of smoking might not be
a consequence of sicca symptoms. Instead, it may influ-
ence the development or progression of the disease. Still,
we cannot exclude that very early dryness, occurring
before the reported onset of symptoms, could influence
the cessation of smoking.
Low levels of formal education and a poor socioeconomic
status have been shown to predict a number of chronic
disorders [17, 26, 38, 39]. In contrast, in the present study,
the level of education and socioeconomic status based on
current occupation had no major impact on the risk of
being diagnosed with pSS. This suggests that the observed
negative association with smoking is probably not due to
underlying exposures related to socioeconomic status,
although we cannot exclude the possibility that other life
style factors contribute to the development of pSS.
Cigarette smoke contains over four thousand different
compounds [40]. Nicotine is known to interact in the im-
mune system and nicotine receptors are present on macro-
phages, T cells and B cells [41–43]. Many other compounds
in cigarette smoke can also affect the immune system [44].
Several studies have shown that cigarette smoke has effects
on the immune system, which reasonably could affect the
development of different diseases. As cigarette smoke,
Table 4 Associations stratified by time from inclusion to diagnosis of primary Sjögren’s syndrome








Smoking Not current smokers Reference 27/87 Reference 23/72
Current smokers 0.3 (0.1–0.9) 4/40 0.3 (0.1–0.8) 6/52
Never smokers Reference 11/58 Reference 7/38
Former smokers 4.9 (1.6–15.2) 16/29 3.4 (1.1–10.8) 16/34
Current smokers 0.5 (0.1–1.8) 4/40 0.5 (0.1–2.0) 6/52
Socioeconomic status White-collar worker Reference 13/65 Reference 13/66
Blue-collar worker 1.4 (0.5–3.8) 11/51 1.3 (0.5–3.7) 11/38
Other 2.0 (0.3–14.3) 2/6 2.6 (0.5–14.4) 4/10
Education Medium/high Reference 18/74 Reference 15/70
Low 1.1 (0.4–2.5) 13/53 1.1 (0.4–3.2) 12/46
Relationship between smoking, socioeconomic status and level of formal education stratified by time from inclusion in the health surveys to diagnosis of primary
Sjögren’s syndrome
Table 5 Immunologic markers at primary Sjögren’s syndrome diagnosis or later by smoking status at inclusion n (% of available)
Current smoker P value* Former smoker P value* Never smoker P value*
Anti-SSApositive, n (%) 8 (80) 0.29 18 (56) 0.60 10 (56) 0.78
Anti- SSB positive, n (%) 7 (70) 0.07 11 (34) 0.43 6 (33) 0.57
ANA positive, n (%) 9 (90) 0.26 20 (63) 0.08 15 (83) 0.35
RF positive, n (%) 4 (44) 0.72 16 (50) 0.60 12 (67) 0.26
Autoantibodya negative 1 (10) 1.00 7 (22) 0.16 1 (6) 0.26
Positive lower lip biopsy, n (%) 8 (80) 0.63 23 (82) 0.71 15 (94) 0.41
Smoking status at inclusion in the health surveys. Primary Sjögren’s syndrome was diagnosed at a median of 8.2 years (IQR 2.4–14.1) after inclusion. *Two-sided
Fisher exact test. aPatients who were negative for anti-Sjögren’s syndrome related antigen A, Ro (anti-SSA), anti-Sjögren’s syndrome related antigen B, La
(anti-SSB), antinuclear antibody (ANA) and rheumatoid factor (RF)
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among other things, is shown to affect neutrophils, macro-
phages, T cells, B cells, dendritic cells, and cytokine produc-
tion (reviewed in [40 − 42]), it is hard to predict exactly
how cigarette smoke might affect the development of pSS
[44–46]. One possible way is by inhibition of B cells: several
studies have identified decreased levels of salivary IgA and
decreased levels of serum IgG, and decreased levels of
serum IgA and IgM and increased levels of IgE in smokers
[46]. Furthermore, significant increases in IgM and IgG in
subjects who stop smoking have been reported [47] and
these changes seem to persist in former smokers for years
after cessation of smoking [48].
pSS is characterized by B-cell activation with high serum
IgG-levels and a high frequency of autoantibodies such as
RF, anti-SSA and anti-SSB [1]. A reason why current smok-
ing could be protective against pSS could be a suppressing
effect of smoking on the B cells directly or by reduced pro-
duction of B-cell activating factor [49, 50]. In predisposed
individuals who stop smoking, taking away the inhibitory
effect of cigarette smoke on the B cells could lead to activa-
tion of autoreactive B cells that might trigger the develop-
ment of the disease. The association between smoking and
anti-citrullinated peptide antibody (ACPA)-positive RA, on
the other hand, most likely reflects other mechanisms spe-
cifically related to RA, such as increased protein citrullina-
tion leading to early development of ACPA [51].
As models of autoimmune diseases and the effect of
cigarette smoking, inflammatory bowel diseases are inter-
esting because smokers have a higher risk of Crohn’s dis-
ease but a lower risk of ulcerative colitis. Studies on
ulcerative colitis and Crohn’s disease have identified dis-
tinct cytokine profiles, whereby Crohn’s disease is charac-
terized by a T helper (Th)1 profile [52, 53], while in
ulcerative colitis a Th2 cytokine profile has been observed
[54, 55], with upregulated levels of IL-33 [56]. IL-33 is a
nuclear cytokine of the IL-1 family, which is constitutively
expressed in epithelial barrier tissues and plays an import-
ant role in Th2 immunity [57]. Recently, increased IL-33
in the salivary glands and in serum have been linked to
pSS [58]. Interestingly, in a murine model, it has also been
shown that exposure of cigarette smoke upregulates IL-33
but simultaneously changes the immune response of IL-
33 from Th2 to Th1 response [59]. Hypothetically, this
could explain why smoking may be protective against ul-
cerative colitis, and potentially also against pSS.
As the patients included in the MSSR are consecutive pa-
tients at the only department of rheumatology in the area,
we consider the patients in the present study to be repre-
sentative of the pSS population. Strengths of the present
study include the study design, with exposure measured in
a standardized manner before pSS diagnosis. The availabil-
ity of two population-based surveys from a well-defined
catchment area and the well-characterized patients with
pSS in the MSSR are other important assets of the study.
Limitations of the study are mainly related to the rela-
tively small number of cases. As the number of patients
is small there is a risk that the patients are not represen-
tative of the whole pSS cohort. Unfortunately, quantita-
tive information on smoking history (i.e. pack-years) was
not available. Furthermore, smoking status was only
assessed at one time point. All patients came from the
same catchment area, which can influence the external
validity of the study. With a disease like pSS, there is
also always uncertainty about when the disease actually
starts. However, in sub-analyses including only cases
with symptom onset after the collection of survey data,
we calculated similar point estimates on the association
between smoking history and pSS, suggesting that re-
versed causality does not explain our findings.
Conclusion
In conclusion, this study shows that current smoking was
associated with a lower risk of later being diagnosed with
pSS, whereas former smoking was associated with a higher
risk. This pattern is similar to that seen in some other
autoimmune diseases, e.g. ulcerative colitis and Parkin-
son’s disease, and may reflect immunomodulatory effects
of smoking and cessation of smoking. These results from
the first nested case-control study of smoking and pSS are
consistent with previous observations from cross-sectional
studies, and suggest that smoking might be protective
against pSS. However, given the insidious onset of the dis-
ease, the limited number of patients included in the
present study and the fact that smoking status was only
assessed at one time point, the results of this study should
be confirmed in subsequent prospective studies.
Abbreviations
ACPA: Anti-citrullinated peptide antibody; AECG criteria: American European
Consensus Group criteria; ANA: Antinuclear antibodies; BAFF: B-cell activating
factor; CI: Confidence interval; IFN: Interferon; Ig: Immunoglobulin;
IL: Interleukin; IQR: Interquartile range; MDCS: Malmö Diet and Cancer study;
MPMP: Malmö Preventive Medicine Program; MSSR: Malmö Sjögren’s
Syndrome Register; pSS: Primary Sjögren’s syndrome; RA: Rheumatoid
arthritis; RF: Rheumatoid factor; SFR: Salivary flow rate; SLE: Systemic lupus
erythematosus; SSA: Sjögren’s syndrome related antigen A, Ro; SSB: Sjögren’s
syndrome related antigen B, La
Acknowledgements
We acknowledge Anders Dahlin for assisting in the gathering of data from the
MPMP and MDCS and Jan-Åke Nilsson for valuable input in the statistical analysis.
Funding
This work was supported by Lund University (ALFSKANE-446501), The
Swedish Rheumatism Association (R-481821), Kockska Stiftelsen and the
Swedish Research Council (2015-02228).
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due to Swedish legislation (the Personal Data Act), but a
limited and fully anonymized dataset containing the individual patient data
that support the main analyses is available from the corresponding author
on reasonable request.
Olsson et al. Arthritis Research & Therapy  (2017) 19:50 Page 6 of 8
Authors’ contributions
PO participated in the study design, the collection of, the statistical analysis and
the interpretation of the results and drafted the manuscript. ET participated in
the study design, the collection of data, the statistical analysis and the
interpretation of the results and helped to revise the manuscript. CT
participated in the study design, the statistical analysis and the interpretation of
the results and helped to revise the manuscript. LJ participated in the
interpretation of the results and helped to revise the manuscript. TM
participated in the interpretation of the results and helped to revise the
manuscript. All authors read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All participants gave their informed consent for inclusion in the MDCS, the
MPMP, and the MSSR. The current study was performed in accordance to
the declaration of Helsinki and was approved by the regional ethical review
board for southern Sweden (Lund, Sweden: 2007/426).
Author details
1Department of Clinical sciences, Malmö, Rheumatology, Lund University,
Malmö, Sweden. 2Department of Rheumatology, Skåne University Hospital,
Lund University, Inga Marie Nilssons gata 32, 20502 Malmö, Sweden.
3Department of Rheumatology and Inflammation research, The Sahlgrenska
Academy, University of Gothenburg, Gothenburg, Sweden.
Received: 4 November 2016 Accepted: 9 February 2017
References
1. Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera
R, Font J, Ingelmo M. Primary Sjogren syndrome: clinical and immunologic
disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;
81(4):270–80.
2. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson
LT. Lymphoma and other malignancies in primary Sjogren’s syndrome: a
cohort study on cancer incidence and lymphoma predictors. Ann Rheum
Dis. 2006;65(6):796–803.
3. Nishishinya MB, Pereda CA, Munoz-Fernandez S, Pego-Reigosa JM, Rua-
Figueroa I, Andreu JL, Fernandez-Castro M, Rosas J, Loza Santamaria E.
Identification of lymphoma predictors in patients with primary Sjogren’s
syndrome: a systematic literature review and meta-analysis. Rheumatol Int.
2015;35(1):17–26.
4. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G. Autoantibodies
present before symptom onset in primary Sjogren syndrome. JAMA. 2013;
310(17):1854–5.
5. Theander E, Jonsson R, Sjostrom B, Brokstad K, Olsson P, Henriksson G.
Prediction of Sjogren’s syndrome years before diagnosis and identification
of patients with early onset and severe disease course by autoantibody
profiling. Arthritis Rheumatol. 2015;67(9):2427–36.
6. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE,
Daniels TE, Fox PC, Fox RI, Kassan SS, et al. Classification criteria for Sjogren’s
syndrome: a revised version of the European criteria proposed by the
American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
7. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of
primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann
Rheum Dis. 2015;74(11):1983–9.
8. Bolstad AI, Jonsson R. Genetic aspects of Sjogren’s syndrome. Arthritis Res.
2002;4(6):353–9.
9. Porola P, Virkki L, Przybyla BD, Laine M, Patterson TA, Pihakari A, Konttinen
YT. Androgen deficiency and defective intracrine processing of
dehydroepiandrosterone in salivary glands in Sjogren’s syndrome. J
Rheumatol. 2008;35(11):2229–35.
10. Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, Piper K,
Jonsson R, Tappuni AR, Pitzalis C, et al. Implication of Epstein-Barr virus
infection in disease-specific autoreactive B cell activation in ectopic lymphoid
structures of Sjogren’s syndrome. Arthritis Rheumatol. 2014;66(9):2545–57.
11. Doll R, Hill AB. Lung cancer and other causes of death in relation to
smoking; a second report on the mortality of British doctors. Br Med J.
1956;2(5001):1071–81.
12. Morgan RW, Jain MG. Bladder cancer: smoking, beverages and artificial
sweeteners. Can Med Assoc J. 1974;111(10):1067–70.
13. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai
S. Impact of smoking as a risk factor for developing rheumatoid arthritis: a
meta-analysis of observational studies. Ann Rheum Dis. 2010;69(1):70–81.
14. Cosnes J. Tobacco and IBD: relevance in the understanding of disease
mechanisms and clinical practice. Best Pract Res Clin Gastroenterology.
2004;18(3):481–96.
15. Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L,
Alfredsson L, Group ES. Smoking is a major preventable risk factor for
rheumatoid arthritis: estimations of risks after various exposures to cigarette
smoke. Ann Rheum Dis. 2011;70(3):508–11.
16. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity,
duration, and cessation, and the risk of rheumatoid arthritis in women. Am
J Med. 2006;119(6):503–9. e1–9.
17. Bergstrom U, Jacobsson LT, Nilsson JA, Wirfalt E, Turesson C. Smoking, low
formal level of education, alcohol consumption, and the risk of rheumatoid
arthritis. Scand J Rheumatol. 2013;42(2):123–30.
18. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel
disease. Dig Dis Sci. 1989;34(12):1841–54.
19. Rizvi SW, McGrath Jr H. The therapeutic effect of cigarette smoking on oral/
genital aphthosis and other manifestations of Behcet’s disease. Clin Exp
Rheumatol. 2001;19(5 Suppl 24):S77–78.
20. van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, van
Laar T, Kromhout H, Vermeulen R. A case-control study of the protective effect of
alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-
cessation modifies the effect of tobacco smoking. PLoS One. 2014;9(4):e95297.
21. Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R,
Nyhagen C, Tabery H, Theander E. Lower frequency of focal lip sialadenitis
(focus score) in smoking patients. Can tobacco diminish the salivary gland
involvement as judged by histological examination and anti-SSA/Ro and anti-
SSB/La antibodies in Sjogren’s syndrome? Ann Rheum Dis. 2000;59(1):54–60.
22. Priori R, Medda E, Conti F, Cassara EA, Sabbadini MG, Antonioli CM, Gerli R,
Danieli MG, Giacomelli R, Pietrogrande M, et al. Risk factors for Sjogren’s
syndrome: a case-control study. Clin Exp Rheumatol. 2007;25(3):378–84.
23. Karabulut G, Kitapcioglu G, Inal V, Kalfa M, Yargucu F, Keser G, Emmungil H,
Gokmen NM, Kocanaogullari H, Aksu K. Cigarette smoking in primary
Sjogren’s syndrome: positive association only with ANA positivity. Mod
Rheumatol. 2011;21(6):602–7.
24. Nilsson PM, Nilsson JA, Berglund G. Family burden of cardiovascular mortality:
risk implications for offspring in a national register linkage study based upon
the Malmo Preventive Project. J Intern Med. 2004;255(2):229–35.
25. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M,
Mattisson I, Berglund G. The Malmo Diet and Cancer Study: representativity,
cancer incidence and mortality in participants and non-participants. Eur J
Cancer Prev. 2001;10(6):489–99.
26. Bergstrom U, Jacobsson LT, Nilsson JA, Berglund G, Turesson C. Pulmonary
dysfunction, smoking, socioeconomic status and the risk of developing
rheumatoid arthritis. Rheumatology (Oxford). 2011;50(11):2005–13.
27. Pikwer M, Bergstrom U, Nilsson JA, Jacobsson L, Berglund G, Turesson C.
Breast feeding, but not use of oral contraceptives, is associated with a
reduced risk of rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):526–30.
28. Pikwer M, Giwercman A, Bergstrom U, Nilsson JA, Jacobsson LT, Turesson C.
Association between testosterone levels and risk of future rheumatoid
arthritis in men: a population-based case-control study. Ann Rheum Dis.
2014;73(3):573–9.
29. Turesson C, Bergstrom U, Pikwer M, Nilsson JA, Jacobsson LT. A high body
mass index is associated with reduced risk of rheumatoid arthritis in men,
but not in women. Rheumatology (Oxford). 2016;55(2):307–14.
30. Turesson C, Bergstrom U, Pikwer M, Nilsson JA, Jacobsson LT. High serum
cholesterol predicts rheumatoid arthritis in women, but not in men: a
prospective study. Arthritis Res Ther. 2015;17:284.
31. Jakobsson K, Jacobsson L, Warrington K, Matteson EL, Liang K, Melander O,
Turesson C. Body mass index and the risk of giant cell arteritis: results from
a prospective study. Rheumatology (Oxford). 2015;54(3):433–40.
32. Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P, Price
EJ, Griffiths B, Hunter J, Gupta M, et al. Cardiovascular risk factors in women
with primary Sjogren’s syndrome: United Kingdom primary Sjogren’s
syndrome registry results. Arthritis Care Res (Hoboken). 2014;66(5):757–64.
33. Perez-De-Lis M, Akasbi M, Siso A, Diez-Cascon P, Brito-Zeron P, Diaz-Lagares
C, Ortiz J, Perez-Alvarez R, Ramos-Casals M, Coca A. Cardiovascular risk
Olsson et al. Arthritis Research & Therapy  (2017) 19:50 Page 7 of 8
factors in primary Sjogren’s syndrome: a case-control study in 624 patients.
Lupus. 2010;19(8):941–8.
34. Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, Bini V,
Alunno A, Bombardieri S, De Vita S, et al. Cardiovascular disease risk burden
in primary Sjogren’s syndrome: results of a population-based multicentre
cohort study. J Intern Med. 2015;278(2):185–92.
35. Khan GJ, Javed M, Ishaq M. Effect of smoking on salivary flow rate. Gomal J
Med Sci. 2010;8(2):221–4.
36. Rad M, Kakoie S, Niliye Brojeni F, Pourdamghan N. Effect of Long-term
Smoking on Whole-mouth Salivary Flow Rate and Oral Health. J Dent Res
Dent Clin Dent Prospects. 2010;4(4):110–4.
37. Sayin N, Kara N, Pekel G, Altinkaynak H. Effects of chronic smoking on
central corneal thickness, endothelial cell, and dry eye parameters. Cutan
Ocul Toxicol. 2014;33(3):201–5.
38. Pincus T, Callahan LF, Burkhauser RV. Most chronic diseases are reported
more frequently by individuals with fewer than 12 years of formal
education in the age 18-64 United States population. J Chronic Dis. 1987;
40(9):865–74.
39. Li X, Sundquist J, Sundquist K. Socioeconomic and occupational risk factors
for rheumatoid arthritis: a nationwide study based on hospitalizations in
Sweden. J Rheumatol. 2008;35(6):986–91.
40. Smith CJ, Hansch C. The relative toxicity of compounds in mainstream
cigarette smoke condensate. Food Chem Toxicol. 2000;38(7):637–46.
41. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H,
Yang H, Ulloa L, et al. Nicotinic acetylcholine receptor alpha7 subunit is an
essential regulator of inflammation. Nature. 2003;421(6921):384–8.
42. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation
of the cholinergic anti-inflammatory system by nicotine attenuates
neuroinflammation via suppression of Th1 and Th17 responses. J Immunol.
2009;183(10):6681–8.
43. Skok MV, Grailhe R, Agenes F, Changeux JP. The role of nicotinic receptors in
B-lymphocyte development and activation. Life Sci. 2007;80(24-25):2334–6.
44. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev
Immunol. 2002;2(5):372–7.
45. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity,
inflammation and autoimmunity. J Autoimmun. 2010;34(3):J258–265.
46. Edwards D. Immunological effects of tobacco smoking in “healthy” smokers.
COPD. 2009;6(1):48–58.
47. Hersey P, Prendergast D, Edwards A. Effects of cigarette smoking on the
immune system. Follow-up studies in normal subjects after cessation of
smoking. Med J Aust. 1983;2(9):425–9.
48. Mili F, Flanders WD, Boring JR, Annest JL, Destefano F. The associations of race,
cigarette smoking, and smoking cessation to measures of the immune system
in middle-aged men. Clin Immunol Immunopathol. 1991;59(2):187–200.
49. Fusby JS, Kassmeier MD, Palmer VL, Perry GA, Anderson DK, Hackfort BT, Alvarez
GK, Cullen DM, Akhter MP, Swanson PC. Cigarette smoke-induced effects on
bone marrow B-cell subsets and CD4+:CD8+ T-cell ratios are reversed by
smoking cessation: influence of bone mass on immune cell response to and
recovery from smoke exposure. Inhal Toxicol. 2010;22(9):785–96.
50. Wang J, Li Q, Xie J, Xu Y. Cigarette smoke inhibits BAFF expression and
mucosal immunoglobulin A responses in the lung during influenza virus
infection. Respir Res. 2015;16:37.
51. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ,
Eklund A, Grunewald J, Skold CM, Klareskog L, Catrina AI. Smoking increases
peptidylarginine deiminase 2 enzyme expression in human lungs and
increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–92.
52. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A,
Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type 1 T-helper cell
predominance and interleukin-12 expression in the gut of patients with
Crohn’s disease. Am J Pathol. 1997;150(3):823–32.
53. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and
ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.
54. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C,
Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion
profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest
increased secretion of IFN-gamma, whereas ulcerative colitis LP cells
manifest increased secretion of IL-5. J Immunol. 1996;157(3):1261–70.
55. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J,
Gitter AH, Burgel N, Fromm M, et al. Interleukin-13 is the key effector Th2
cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis,
and cell restitution. Gastroenterology. 2005;129(2):550–64.
56. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama
Y, Andoh A. Interleukin-33 expression is specifically enhanced in inflamed
mucosa of ulcerative colitis. J Gastroenterol. 2010;45(10):999–1007.
57. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond).
2011;8(1):22.
58. Awada A, Nicaise C, Ena S, Schandene L, Rasschaert J, Popescu I, Gangji V,
Soyfoo MS. Potential involvement of the IL-33-ST2 axis in the pathogenesis
of primary Sjogren’s syndrome. Ann Rheum Dis. 2014;73(6):1259–63.
59. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, Mori M, Pham TH,
Ward CK, Criner GJ, et al. Cigarette smoke silences innate lymphoid cell
function and facilitates an exacerbated type I interleukin-33-dependent
response to infection. Immunity. 2015;42(3):566–79.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Olsson et al. Arthritis Research & Therapy  (2017) 19:50 Page 8 of 8
